Gadde Ashwini, Bansal Shyam B, Dhampalwar Swapnil, Choudhary Narendra Singh, Jha Pranaw, Rana Abhyuday K, Saraf Neeraj
Department of Nephrology and Renal Transplant, Fortis Memorial Research Institute, Gurugram, Haryana, India.
Department of Nephrology, Kidney and Urology Institute, Medanta The Medicity, Gurugram, Haryana, India.
Indian J Nephrol. 2025 May-Jun;35(3):385-389. doi: 10.25259/IJN_28_2024. Epub 2024 Aug 1.
There is a lack of data regarding the need for liver transplantation in end-stage kidney disease (ESKD) patients with compensated cirrhosis. Overall outcomes of isolated kidney transplants in these patients in terms of renal graft outcome, hepatic decompensation, and survival are less clear.
This is the retrospective analysis of patients treated at a single center. Patients with cirrhosis with evidence of portal hypertension who underwent kidney transplantation were compared with a matched control group without chronic liver disease (CLD) who underwent kidney transplantation during the same period.
Nineteen CLD patients with evidence of portal hypertension confirmed by endoscopy showing varices (8/19), hepatic venous pressure gradient (HVPG) >5 (12/19), or portosystemic collaterals on imaging (8/19) underwent kidney transplantation and were compared with 38 patients without liver disease transplanted during the same period. The discharge of creatinine was similar in both groups. The median follow-up was approximately 4 years in both groups, with the last mean serum creatinine of 1.3 and 1.37 mg/dl (unit for creatinine) in the patient and control groups (P = 0.382). Biopsy-proven acute rejections were similar [3 (15.8%) vs. 7 (18.4%), p = 1]. Two patients died in the CLD group, one due to hepatic decompensation with sepsis and the other due to cardiac cause. Four patients died in the control group (3 with sepsis and 1 with cardiac cause). Two patients had liver decompensation post-transplant (1-month post-transplant with ascites, 4 years post-transplant with ascites and hepatic encephalopathy).
Kidney-alone transplantation in a carefully selected population with CLD and portal hypertension has comparable outcomes to those without liver disease.
对于患有代偿期肝硬化的终末期肾病(ESKD)患者,关于肝移植需求的数据匮乏。这些患者单纯肾移植在肾移植结局、肝失代偿和生存方面的总体结果尚不清楚。
这是一项对单中心治疗患者的回顾性分析。将接受肾移植的有门静脉高压证据的肝硬化患者与同期接受肾移植的无慢性肝病(CLD)的匹配对照组进行比较。
19例经内镜证实有门静脉高压证据(表现为静脉曲张8例/19例、肝静脉压力梯度(HVPG)>5 12例/19例或影像学显示门体侧支循环8例/19例)的CLD患者接受了肾移植,并与同期38例无肝病的移植患者进行比较。两组患者出院时的肌酐水平相似。两组的中位随访时间约为4年,患者组和对照组的最后平均血清肌酐分别为1.3和1.37mg/dl(肌酐单位)(P = 0.382)。活检证实的急性排斥反应相似[3例(15.8%)对7例(18.4%),p = 1]。CLD组有2例患者死亡,1例死于肝失代偿合并败血症,另1例死于心脏原因。对照组有4例患者死亡(3例死于败血症,1例死于心脏原因)。2例患者移植后出现肝失代偿(1例移植后1个月出现腹水,1例移植后4年出现腹水和肝性脑病)。
在精心挑选的患有CLD和门静脉高压的人群中进行单纯肾移植,其结局与无肝病患者相当。